For indlæggelser af kardiovaskulære årsager (1 234 eller 28% af det samlede antal) var der derimod en signifikant reduktion på 10, 8% (95% SI [4- 17, 4], p = 0, 01) i pravastatingruppen.
However, for cardiovascular causes (1,234 or 28% of the total), there was a significant 10.8% reduction in admissions (95% CI [4-17.4], p = 0.01) in the pravastatin group.